Skip to content


Tradjenta, Trajenta (linagliptin) is a small molecule pharmaceutical. Linagliptin was first approved as Tradjenta on 2011-05-02. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against dipeptidyl peptidase 4. Tradjenta's patents are valid until 2031-03-05 (FDA).
Trade Name Trajenta
Common Name Linagliptin
Indication type 2 diabetes mellitus
Drug Class Dipeptidyl aminopeptidase-IV inhibitors
Get full access now